PMID- 33599247
OWN - NLM
STAT- MEDLINE
DCOM- 20220111
LR  - 20220111
IS  - 1460-2393 (Electronic)
IS  - 1460-2725 (Print)
IS  - 1460-2393 (Linking)
VI  - 114
IP  - 11
DP  - 2022 Jan 5
TI  - Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized 
      controlled double-blind, dose-response study in Lagos.
PG  - 780-788
LID - 10.1093/qjmed/hcab035 [doi]
LID - hcab035
AB  - INTRODUCTION: In vitro studies have shown the efficacy of Ivermectin (IV) to 
      inhibit the SARS-CoV-2 viral replication, but questions remained as to in-vivo 
      applications. We set out to explore the efficacy and safety of Ivermectin in 
      persons infected with COVID19. METHODS: We conducted a translational proof of 
      concept randomized, double blind placebo controlled, dose response and parallel 
      group study of IV efficacy in RT-polymerase chain reaction proven COVID 19 
      positive patients. Sixty-two patients were randomized to three treatment groups. 
      (A) IV 6 mg regime, (B) IV 12 mg regime (given Q84 h for 2 weeks) (C, control) 
      Lopinavir/Ritonavir. All groups plus standard of Care. RESULTS: The Days to COVID 
      negativity (DTN) was significantly and dose dependently reduced by IV 
      (P = 0.0066). The DTN for Control were, = 9.1+/-5.2, for A 6.0 +/- 2.9 and for B 
      4.6 +/-3.2. Two way repeated measures ANOVA of ranked COVID 19 +/- scores at 0, 
      84, 168 and252h showed a significant IV treatment effect (P = 0.035) and time 
      effect (P < 0.0001). IV also tended to increase SPO2% compared to controls, 
      P = 0.073, 95% CI-0.39 to 2.59 and increased platelet count compared to C 
      (P = 0.037) 95%CI 5.55-162.55 x 103/ml. The platelet count increase was inversely 
      correlated to DTN (r = -0.52, P = 0.005). No SAE was reported. CONCLUSIONS: 12mg 
      IV regime given twice a week may have superior efficacy over 6mg IV given twice a 
      week, and certainly over the non IV arm of the study. IV should be considered for 
      use in clinical management of SARS-COV2, and may find applications in prophylaxis 
      in high risk areas.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the 
      Association of Physicians. All rights reserved. For permissions, please email: 
      journals.permissions@oup.com.
FAU - Babalola, O E
AU  - Babalola OE
AD  - From the Department of Ophthalmology, Bingham University, Karu/Jos, 
      Nassarawa/Plateau state, Nigeria.
FAU - Bode, C O
AU  - Bode CO
AD  - Department of Surgery, College of Medicine and Lagos University Teaching 
      Hospital, Lagos, Nigeria.
FAU - Ajayi, A A
AU  - Ajayi AA
AD  - Division of Hypertension and Clinical pharmacology, Keck Department of Medicine, 
      Baylor College of Medicine Houston Texas, TX 77030, USA.
FAU - Alakaloko, F M
AU  - Alakaloko FM
AD  - Department of Surgery, Lagos University Teaching Hospital, Lagos, Nigeria.
FAU - Akase, I E
AU  - Akase IE
AD  - Department of Medicine, Lagos University Teaching Hospital, Lagos, Nigeria.
FAU - Otrofanowei, E
AU  - Otrofanowei E
AD  - Department of Medicine, Faculty of Clinical Sciences, College of Medicine/Lagos 
      University Teaching Hospital, Lagos, Nigeria.
FAU - Salu, O B
AU  - Salu OB
AD  - Central Research Laboratory/Department of Medical Microbiology and Parasitology, 
      Centre for Human and Zoonotic Virology, College of Medicine, University of Lagos, 
      Lagos, Nigeria.
FAU - Adeyemo, W L
AU  - Adeyemo WL
AD  - Department of Oral and Maxillofacial Surgery, College of Medicine, University of 
      Lagos, Lagos, Nigeria.
FAU - Ademuyiwa, A O
AU  - Ademuyiwa AO
AD  - Department of Surgery, College of Medicine and Lagos University Teaching 
      Hospital, Lagos, Nigeria.
FAU - Omilabu, S
AU  - Omilabu S
AD  - Central Research Laboratory/Department of Medical Microbiology and Parasitology, 
      Centre for Human and Zoonotic Virology, College of Medicine, University of Lagos, 
      Lagos, Nigeria.
LA  - eng
GR  - The Central Bank of Nigeria Health Sector Research and Development Intervention 
      Scheme (CBN HSRDIS)/
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - QJM
JT  - QJM : monthly journal of the Association of Physicians
JID - 9438285
RN  - 0 (RNA, Viral)
RN  - 70288-86-7 (Ivermectin)
SB  - IM
MH  - *COVID-19
MH  - Double-Blind Method
MH  - Humans
MH  - *Ivermectin
MH  - Nigeria
MH  - Oxygen Saturation
MH  - RNA, Viral
MH  - SARS-CoV-2
MH  - Treatment Outcome
PMC - PMC7928689
EDAT- 2021/02/19 06:00
MHDA- 2022/01/12 06:00
PMCR- 2021/03/03
CRDT- 2021/02/18 08:38
PHST- 2021/01/08 00:00 [received]
PHST- 2021/01/29 00:00 [revised]
PHST- 2021/02/19 06:00 [pubmed]
PHST- 2022/01/12 06:00 [medline]
PHST- 2021/02/18 08:38 [entrez]
PHST- 2021/03/03 00:00 [pmc-release]
AID - 6143037 [pii]
AID - hcab035 [pii]
AID - 10.1093/qjmed/hcab035 [doi]
PST - ppublish
SO  - QJM. 2022 Jan 5;114(11):780-788. doi: 10.1093/qjmed/hcab035.